Equities

Intellego Technologies AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Intellego Technologies AB

Actions
  • Price (SEK)46.55
  • Today's Change0.00 / 0.00%
  • Shares traded1.45m
  • 1 Year change+20.60%
  • Beta0.9131
Data delayed at least 15 minutes, as of Nov 17 2025 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Intellego Technologies AB is a Sweden-based company engaged in photochromatic indicator technology. The Company is a manufacturer of colorimetric ultraviolet indicators. UVC Dosimeters are used in Healthcare, Hospitality, Retail, Transportation and Commercial Applications around the world. With its patented photochromic ink that changes color based on exposure to ultraviolet irradiation or specific substances, Intellego produces dosimeters in a variety of formats and custom options to meet the constantly evolving needs of Ultraviolet Device Manufacturers (OEMs) and end-users. Intellego Technologies is headquartered in Stockholm, with product development and manufacturing based in the southwest region of Sweden.

  • Revenue in SEK (TTM)770.81m
  • Net income in SEK294.66m
  • Incorporated2011
  • Employees65.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nykode Therapeutics ASA60.84m-98.85m904.69m62.00--1.01--14.87-0.3148-0.31480.19742.930.0494--1.91470,088.80-8.032.32-8.662.60-----162.468.51----0.0284---32.73---10.43---1.35--
XSpray Pharma AB (publ)0.00-216.42m968.42m26.00--1.51-----5.96-5.960.0015.370.00----0.00-29.09-23.48-30.93-25.08--------5.93-18.440.1883-------58.92---14.46--
Curasight A/S-63.78m-68.87m1.07bn4.00--43.06-----1.13-1.13-1.070.3809-1.52-----11,171,250.00-163.63-37.34-313.58-40.89-----------16.540.00---27.21---40.76------
Cantargia AB308.69m139.93m1.32bn23.0010.464.439.194.270.50680.50681.331.201.41--164.0214,031,360.0063.91-56.5680.65-63.93----45.33----76.550.00------42.27------
Nightingale Health Oyj50.04m-196.84m1.42bn100.00--1.46--28.44-0.3052-0.30520.07781.100.05680.94442.7946,930.00-22.33-15.66-24.26-16.9575.3975.21-393.39-447.178.52--0.0511--7.6921.38-5.71---12.69--
Solar Foods Oyj203.76k-113.72m1.48bn57.00--6.52--7,255.91-0.433-0.4330.00080.71150.0004--0.0037455.00-22.45---27.05--25,931.57---55,808.37-----7.030.5092--275.15---22.57------
Intellego Technologies AB770.81m294.66m1.55bn65.004.752.334.812.019.819.8125.9120.011.2810.592.3212,432,400.0049.1117.1361.6423.8770.9758.8238.2321.324.115.350.0617--42.25222.7114.78------
Thor Medical ASA93.11k-54.85m1.57bn13.00--3.50--16,836.36-0.223-0.2230.00041.360.0002--0.007811,111.11-13.37-59.74-13.90-81.16-----58,908.00--8.78--0.018-------659.00---33.37--
BioInvent International AB244.85m-323.94m1.71bn124.00--2.50--6.99-4.91-4.913.7210.380.2614--4.902,147,790.00-34.58-19.38-38.20-20.57-----132.30-189.977.31--0.0154---37.47-13.77-29.99--21.19--
Devyser Diagnostics AB242.80m-25.20m1.81bn115.00--5.291,289.477.44-1.52-1.5214.6620.480.52621.405.531,839,394.00-5.64-10.61-6.60-12.0481.9680.33-10.71-28.672.27-2.030.1312--28.1227.53-14.74--52.54--
Egetis Therapeutics AB (publ)55.40m-333.40m1.97bn40.00--6.44--35.49-0.9376-0.93760.15540.77250.094545.531.931,582,857.00-56.85-36.53-87.92-41.5230.1481.16-601.62-558.740.7971-45.060.249---19.97-11.00-5.11------
Cereno Scientific AB0.00-113.30m2.09bn5.00--10.23-----0.3987-0.39870.000.65720.00-------30.72-20.10-32.58-21.72-----------1.940.4817-------106.89--47.93--
Diamyd Medical AB348.00k-182.46m2.19bn41.00--9.72--6,307.08-1.52-1.520.00291.680.0013--18.818,923.08-69.46-44.47-76.54-49.74-----52,430.46-31,802.45----0.1628--0.00-17.54-11.81--38.40--
Data as of Nov 17 2025. Currency figures normalised to Intellego Technologies AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025775.24k0.00%
American Century Investment Management, Inc.as of 08 Jan 2026342.58k0.00%
Baader Bank AG (Investment Management)as of 28 Nov 2025240.00k0.00%
Mandarine Gestion SAas of 30 Jun 2025159.50k0.00%
Philippe Hottinguer & Cie Gestion SASas of 30 Jun 202596.46k0.00%
RAM Active Investments SAas of 30 Jun 202562.00k0.00%
Laiqon AG (Investment Management)as of 28 Nov 202520.00k0.00%
SSgA Funds Management, Inc.as of 08 Jan 202616.56k0.00%
IRIVEST Investment Managersas of 30 Nov 202511.45k0.00%
Atlant Fonder ABas of 30 Jan 20260.000.00%
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.